266 related articles for article (PubMed ID: 19826119)
1. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.
Lin TS; Ruppert AS; Johnson AJ; Fischer B; Heerema NA; Andritsos LA; Blum KA; Flynn JM; Jones JA; Hu W; Moran ME; Mitchell SM; Smith LL; Wagner AJ; Raymond CA; Schaaf LJ; Phelps MA; Villalona-Calero MA; Grever MR; Byrd JC
J Clin Oncol; 2009 Dec; 27(35):6012-8. PubMed ID: 19826119
[TBL] [Abstract][Full Text] [Related]
2. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.
Phelps MA; Lin TS; Johnson AJ; Hurh E; Rozewski DM; Farley KL; Wu D; Blum KA; Fischer B; Mitchell SM; Moran ME; Brooker-McEldowney M; Heerema NA; Jarjoura D; Schaaf LJ; Byrd JC; Grever MR; Dalton JT
Blood; 2009 Mar; 113(12):2637-45. PubMed ID: 18981292
[TBL] [Abstract][Full Text] [Related]
3. Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.
Byrd JC; Lin TS; Dalton JT; Wu D; Phelps MA; Fischer B; Moran M; Blum KA; Rovin B; Brooker-McEldowney M; Broering S; Schaaf LJ; Johnson AJ; Lucas DM; Heerema NA; Lozanski G; Young DC; Suarez JR; Colevas AD; Grever MR
Blood; 2007 Jan; 109(2):399-404. PubMed ID: 17003373
[TBL] [Abstract][Full Text] [Related]
4. Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Maddocks K; Wei L; Rozewski D; Jiang Y; Zhao Y; Adusumilli M; Pierceall WE; Doykin C; Cardone MH; Jones JA; Flynn J; Andritsos LA; Grever MR; Byrd JC; Johnson AJ; Phelps MA; Blum KA
Am J Hematol; 2015 Apr; 90(4):327-33. PubMed ID: 25639448
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
Byrd JC; Peterson BL; Gabrilove J; Odenike OM; Grever MR; Rai K; Larson RA;
Clin Cancer Res; 2005 Jun; 11(11):4176-81. PubMed ID: 15930354
[TBL] [Abstract][Full Text] [Related]
6. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors.
Ramaswamy B; Phelps MA; Baiocchi R; Bekaii-Saab T; Ni W; Lai JP; Wolfson A; Lustberg ME; Wei L; Wilkins D; Campbell A; Arbogast D; Doyle A; Byrd JC; Grever MR; Shah MH
Invest New Drugs; 2012 Apr; 30(2):629-38. PubMed ID: 20938713
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.
Stephens DM; Ruppert AS; Maddocks K; Andritsos L; Baiocchi R; Jones J; Johnson AJ; Smith LL; Zhao Y; Ling Y; Li J; Phelps MA; Grever MR; Byrd JC; Flynn JM
Leuk Res; 2013 Oct; 37(10):1195-9. PubMed ID: 23867058
[TBL] [Abstract][Full Text] [Related]
8. Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia.
Lanasa MC; Andritsos L; Brown JR; Gabrilove J; Caligaris-Cappio F; Ghia P; Larson RA; Kipps TJ; Leblond V; Milligan DW; Janssens A; Johnson AJ; Heerema NA; Bühler A; Stilgenbauer S; Devin J; Hallek M; Byrd JC; Grever MR
Leuk Res; 2015 May; 39(5):495-500. PubMed ID: 25804339
[TBL] [Abstract][Full Text] [Related]
9. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol in chronic lymphocytic leukemia: a concise review.
Christian BA; Grever MR; Byrd JC; Lin TS
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S179-85. PubMed ID: 19778838
[TBL] [Abstract][Full Text] [Related]
11. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
12. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
Blum KA; Ruppert AS; Woyach JA; Jones JA; Andritsos L; Flynn JM; Rovin B; Villalona-Calero M; Ji J; Phelps M; Johnson AJ; Grever MR; Byrd JC
Leukemia; 2011 Sep; 25(9):1444-51. PubMed ID: 21606960
[TBL] [Abstract][Full Text] [Related]
14. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
Flinn IW; Byrd JC; Bartlett N; Kipps T; Gribben J; Thomas D; Larson RA; Rai K; Petric R; Ramon-Suerez J; Gabrilove J; Grever MR
Leuk Res; 2005 Nov; 29(11):1253-7. PubMed ID: 15916806
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy.
Awan FT; Jones JA; Maddocks K; Poi M; Grever MR; Johnson A; Byrd JC; Andritsos LA
Ann Hematol; 2016 Jun; 95(7):1137-43. PubMed ID: 27118540
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
17. Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies.
Lin TS
Clin Lymphoma Myeloma; 2008 Aug; 8 Suppl 4():S137-43. PubMed ID: 18952544
[TBL] [Abstract][Full Text] [Related]
18. Update in the management of chronic lymphocytic leukemia.
Maddocks KJ; Lin TS
J Hematol Oncol; 2009 Jul; 2():29. PubMed ID: 19619273
[TBL] [Abstract][Full Text] [Related]
19. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.
Roberts AW; Davids MS; Pagel JM; Kahl BS; Puvvada SD; Gerecitano JF; Kipps TJ; Anderson MA; Brown JR; Gressick L; Wong S; Dunbar M; Zhu M; Desai MB; Cerri E; Heitner Enschede S; Humerickhouse RA; Wierda WG; Seymour JF
N Engl J Med; 2016 Jan; 374(4):311-22. PubMed ID: 26639348
[TBL] [Abstract][Full Text] [Related]
20. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
